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Cyclooxygenase-2 (Cox-2) is rapidly expressed by various stimuli and plays a key role in conversion of
free arachidonic acid to prostaglandins. We have previously identiﬁed 4-hydroxy-2-nonenal (HNE), a
lipid peroxidation-derived electrophile, as the potent Cox-2 inducer in rat epithelial RL34 cells and re-
vealed that the HNE-induced Cox-2 expression resulted from the stabilization of Cox-2 mRNA that is
mediated by the p38 mitogen-activated protein kinase signaling pathway. In the present study, we in-
vestigated an alternative regulatory mechanism of Cox-2 expression mediated by a transcription factor
p53. In addition, to characterize the causal role for Cox-2, we examined the effects of Cox-2 over-
expression in RL34 cells. To examine whether the HNE-induced Cox-2 expression was mechanistically
linked to the p53 expression, we analyzed changes in Cox-2 and p53 expression levels in response to
HNE and observed that the Cox-2 levels were inversely correlated with the p53 levels. Down-regulation
of p53 followed by the activation of a transcription factor Sp1 was suggested to be involved in the HNE-
induced Cox-2 gene expression. To characterize the effect of Cox-2 expression in the cells, we established
the Cox-2-overexpressing derivatives of RL34 cells by stable transfection with Cox-2 cDNA. An oligo-
nucleotide microarray analysis revealed a dramatic down-regulation of the proteasome subunit RC1 in
the Cox-2 overexpressed cells compared to the empty-vector transfected control cells. Consistent with
the Cox-2-mediated down-regulation of proteasome, a moderate reduction of the proteasome activities
was observed. This proteasome dysfunction mediated by the Cox-2 overproduction was associated with
the enhanced accumulation of p53 and ubiquitinated proteins, leading to the enhanced sensitivity to-
ward electrophiles. These results suggest the existence of a causal link between Cox-2 and p53, which
may represent a toxic mechanism of electrophilic lipid peroxidation products.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Cyclooxygense (Cox), also termed prostaglandin H synthase, is
the enzyme catalyzing the rate-limiting step that converts free
arachidonic acid to prostaglandin (PG) H2 on the arachidonic
cascade [1]. Presently, three isoforms, Cox-1, Cox-2, and Cox-3
have been identiﬁed. Cox-1 is present under normal conditions inB.V. This is an open access article u
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hida).most tissues and is responsible for housekeeping functions. On the
other hand, Cox-2 is not normally present under the basal condi-
tions or is present in very low amounts. However, it is rapidly
induced in response to a wide variety of cytokines [2], growth
factors [3], and ligands of G protein-coupled receptors [4]. The
induction of the Cox-2 gene is regulated at both transcriptional
(promoter-based) and post-transcriptional levels [3,5,6]. Intrigu-
ingly, Subbaramaiah et al. [7] have suggested that Cox-2 gene
expression is negatively regulated by p53, implying functional
interactions of Cox-2 with p53. Cox-3 is a splice variant of Cox-1
that shares the catalytic features of Cox-1 and Cox-2 and has a
sensitivity for acetaminophen [8].
The tumor suppressor protein p53 is a transcription factor
that regulates the response to a variety of stimuli such as DNA
damage, hypoxia, oxidative stress, and oncogene expression [9].nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
T. Kumagai et al. / Redox Biology 4 (2015) 74–86 75Inactivation of the p53 gene, either by mutation or deletion, has
frequently been found in a variety of human malignant tumors
[10,11]. Under normal conditions, p53 is a very labile protein. The
rapid degradation of p53 is largely achieved through the ubiqui-
tin–proteasome pathway. However, once cells are exposed to sti-
muli, the p53 protein increases promptly and regulates the various
gene expressions. The accumulation of p53 protein in response to
various stimuli occurs mainly through post-translational mod-
iﬁcation rather than the transcriptional level. p53 has many
phosphorylation sites, and the phosphorylation status of p53 is
thought to be involved in stabilization and function of the protein
[12]. p53 exerts its role through the transcriptional regulation of
genes involved in cell cycle control, DNA repair, senescence, and
apoptosis. p53 increases the gene expression involved in the cell
cycle and apoptosis such as p21 [13], MDM2 [14], Bcl-2 [15] and
Bax [16]. On the other hand, p53 also represses the transcription of
a number of genes, including topoisomerase IIα [17], MRP [18],
and human reduced folate carrier [19].
Lipid peroxidation proceeds by a free radical chain reaction
mechanism and yields lipid hydroperoxides as major initial reac-
tion products. A key feature of the lipid peroxidation is the
breakdown of these hydroperoxy fatty acids to yield a broad array
of smaller fragments, 3–9 carbons in length, including reactive
aldehydes, such as 2-alkenals and 4-hydroxy-2-alkenals [20–22].
There is increasing evidence that these aldehydes are causally
involved in many of the pathophysiological effects associated with
oxidative stress in cells and tissues. In view of the observation that
liver injury associated with oxidative stress is accompanied by
increased PG synthesis [23], it is hypothesized that lipid perox-
idation products may be involved in the up-regulation of the PG
biosynthesis. Our previous ﬁnding [24] that 4-hydroxy-2-nonenal
(HNE), one of the major lipid peroxidation-derived electrophilic
aldehydes, was identiﬁed as a potent Cox-2 inducer in rat epi-
thelial RL34 cells supports this hypothesis. Moreover, we have
revealed that HNE-induced Cox-2 expression resulted from the
stabilization of Cox-2 mRNA that is mediated by the p38 mitogen-
activated protein kinase (MAPK) signaling pathway [25]. In the
present study, to examine whether the HNE-induced Cox-2 ex-
pression was mechanistically linked to the p53 expression, we
analyzed changes in Cox-2 and p53 expression levels in response
to HNE. Our data show that HNE-induced down-regulation of p53
is involved in the enhanced Cox-2 gene expression, probably
through the activation of transcription factor Sp1. Moreover, using
Cox-2-overexpressing derivatives of RL34 cells, we show that Cox-
2 overproduction is associated with down-regulation of a protea-
some subunit. The resultant proteasome dysfunction results in the
enhanced accumulation of p53 and ubiquitinated proteins, leading
to enhanced sensitivity toward electrophiles.Experimental procedures
Materials
HNE was obtained from Cayman Chemical Co. (Ann Arbor, MI).
Anti-Cox-2, anti-Sp1 and anti-p53 polyclonal antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
GenePORTER transfection reagent was obtained from Gene Ther-
apy Systems, Inc. (San Diego, CA). and opti-MEM 1 reduced serum
medium and the First-Strand cDNA synthesis kit were from Life
Technologies, Inc. (Rockville, MD, USA). Horseradish peroxidase-
linked anti-goat IgG was from DAKO Co. (A/S, Denmark). Anti-
rabbit IgG immunoglobulin-conjugated horseradish peroxidase,
enhanced chemiluminescence (ECL) western blotting detection
reagents and Hybond ECL nitrocellulose membranes were ob-
tained from Amersham (Piscataway, NJ). The protein concentrationwas measured using the BCA protein assay reagent obtained from
Pierce Chemical Co.
Cell culture
RL34 rat liver epithelial-like cells were obtained from the Ja-
panese Cancer Research Resources Bank. The cells were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) containing heat-
inactivated 5% fetal bovine serum (FBS), penicillin (100 U/ml),
streptomycin (100 mg/ml), L-glutamine (588 mg/ml), and 0.16%
NaHCO3. Cells were cultured in a 37 °C humidiﬁed atmosphere
containing 95% air/5% CO2. 50–60% Conﬂuent cells were subjected
to experiments in DMEM containing 5% FBS.
Cox-2 construct
Rat Cox-2 cDNA containing open reading frame was ampliﬁed
by RT-PCR, using a set of primer that contained an EcoRV restric-
tion site. After digestion with EcoRV, the ampliﬁed Cox-2 cDNA
fragment was ligated into the EcoRV site of a linearized pCMV-
Script expression vector (Stratagene, CA) using T4 DNA ligase to
create the sense rat Cox-2 construct. The resulting expression
plasmid was veriﬁed by restriction enzyme digestion and
was named pcCox-2 vector. The primer used for rat Cox-2
full coding region ampliﬁcation is as follows: (F), 5′-GA-
TATCCTTCAGGAGTACGAAGACCCTGCCTAC-3′ and (R), 5′-GA-
TATCATGGTAAGTAGACTCTTACAGCTCAG-3′.
Stable transfection with Cox-2 in RL34 cells
RL34 cells were transfected with pcCox-2 vector or with empty
control vector using the GenePORTER™ transfection reagent (Gene
Therapy Systems, Inc.). In these experiments, 1106 cells were
incubated with the DNA-GenePORTER mixture (2 mg of DNA/10 μl
of GenePORTER) in 1 ml of serum-free Opti-MEM1 (GIBCO) at
37 °C. After 6 h of incubation, 1 ml of the complete medium was
added, and the cells were cultured for 18 h. Thereafter, stable
transfectants were isolated by culture in selection medium con-
taining 700 mg/ml G418 for 3 weeks. A single clone of the stably
transfected cells was isolated and expanded. Several G418-re-
sistant stable clones were maintained in regular growth medium
containing 700 mg/ml G418.
PGD2 assay
A solid phase enzyme immunoassay (Cayman Chemical) was
performed as suggested by the manufacturer, and the PGD2 level
was determined using a standard curve and a linear log–logit
transformation.
Oligonucleotide microarray
Total RNAs were isolated from the empty vector—the trans-
fected control and Cox-2-transfected cells independently using
Isogen (Nippon Gene, Tokyo, Japan) according to the manufac-
turer's protocol. The quality of the extracted total RNA was con-
ﬁrmed with an Agilent 2100 Bioanalyzer (Palo Alto, CA) or elec-
trophoresis on 1.5% agarose gels stained by SYBR Green (Applied
Biosystems, Foster City, CA). Double-stranded complementary
DNA was synthesized from 10 mg of total RNA according to Affy-
metrix (Affymetrix, Santa Clara, CA) methodology, and cDNA was
puriﬁed with Phase Lock Gels (Eppendorf, Hamburg, Germany).
We synthesized biotin-labeled RNA with the BioArray High Yield
RNA Transcript Labeling Kit (Enzo, New York, NY). Hybridization
from biotinylated cRNA to murine genome GeneChips (MG-
U74Av2, Affymetrix) was performed in accordance with the
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in a mix that included 10 mg fragmented RNA, 6 SSPE, 0.005%
Triton X-100, and 100 mg/ml herring sperm DNA in a total volume
of 200 ml. The GeneChips were washed and stained with strepta-
vidin-c (Molecular Probes, Eugene, OR), and probe arrays were
scanned three times at 3-mm resolution using the GeneChip sys-
tem confocal scanner made for Affymetrix by Hewlett-Packard.
MicroArray Suite (MAS) version 5.1 (Affymetrix) was utilized to
calculate from the scanned images. Intensity values were scaled
such that the overall intensity for each GeneChip of the same type
was equivalent [26]. The average difference of each experiment
was normalized to 100 to allow comparison among multiple
arrays.
Cell viability
Cell viability was quantiﬁed by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay as previously de-
scribed [27].
p53 antisense oligonucleotides transfection
Thiophosphorylated antisense oligonucleotides were pur-
chased from Sigma Genosys Japan Co. RL34 cells were seeded at a
density of 1105 cells/35 mm dish and grown for 24 h in medium
containing 5% FBS. Transient transfections were performed
using the GenePORTER reagent according to the manufacturer's
protocols. Brieﬂy, the indicated concentration of oligonucleotides
was prepared in 100 ml opti-MEM1 and incubated with 7 μl
GenePORTER reagent prepared separately in 100 ml opti-MEM1.
After 15 min, the DNA–reagent complexes were added to cells
that had been washed with opti-MEM1 medium and incubated
for 6 h. The medium was then changed to fresh medium con-
taining 5% FBS, maintained for another 48 h, and subjected to the
experiment.
Immunoblot analysis
The HNE-treated or untreated cells were washed twice with
phosphate-buffered saline (pH 7.0) and lysed with RIPA buffer
(50 mM Tris–HCl (pH 7.5)/150 mM NaCl/1% Triton X-100/0.5% so-
dium deoxycholate/0.1% SDS/100 mg/ml phenylmethylsulfonyl
ﬂuoride (PMSF)). Each whole cell lysate (total protein, 25 mg) was
then treated with Laemmli sample buffer for 5 min at 100 °C [28].
The samples were run on 10% SDS-polyacrylamide gels and blotted
on a nitrocellulose membrane (Amersham Bioscience), incubated
with 4% Block Ace (Dainippon Pharmaceutical Co., Osaka, Japan)
overnight at 4 °C for blocking, washed with TTBS, and treated with
the antibodies to p53 or Sp1. This procedure was followed by the
addition of horseradish peroxidase conjugated to IgG and ECL re-
agents. The bands were detected with Light-Capture (ATTO Co.,
Tokyo, Japan).
Immunoprecipitation
The whole cell lysate was prepared as described above, and
2 mg protein of each sample was incubated with protein A-se-
pharose beads (Pharmacia Bioscience) to remove nonspeciﬁc
binding proteins at 4 °C for 1 h. After centrifugation, the super-
natants were mixed with 2 mg of antibodies to p53 or Sp1 and then
incubated at 4 °C with rotation overnight. Following the incuba-
tion with protein A-sepharose beads for 1 h, the antigen–anti-
body-beads complex was washed 4 times with the RIPA buffer and
3 times with PBS, boiled for 5 min after adding 30 ml of 3 SDS-
PAGE sample buffer and subjected to immunoblot analysis.RNA isolation and reverse transcription-polymerase chain reaction
(RT-PCR)
Total RNA was isolated from cells using ISOGEN reagent (Nip-
pon Gene Co., Tokyo, Japan) according to the manufacturer's pro-
tocol and spectrophotometrically quantiﬁed. First-strand cDNA
was synthesized at 37 °C for 60 min with 5 mg of total RNA using
an oligo(dT) primer and MMLV-RNA polymerase (Invitrogen). To
stop the reaction the samples were heated at 95 °C for 2 min. PCR
reactions were carried out in a ﬁnal volume of 25 ml consisting of
10 mM Tris–HCl (pH 8.3), 50 mM KCl, 0.1% Triton-X 100, 200 mM
amounts of each deoxyribonucleoside triphosphate, 0.5 ml of the
RT ﬁrst-strand cDNA product, 1 mM of each forward and reverse
primer, and 2.5 units of rTaq DNA polymerase (Toyobo Co., Osaka,
Japan). After the initial denaturation step for 3 min at 94 °C,
26 cycles of PCR were performed. Each cycle consisted of a
denaturing step at 94 °C for 30 s, an annealing step at 54 °C for
30 s, and extension step at 72 °C for 30 s. After the cycling
procedure, a ﬁnal 10-min elongation step at 72 °C was performed.
The following primers were used: Cox-2, (F) 5′-CCCTGCTGGTG
GAAAAGCCTGGTCC-3′ and (R) 5′TACTGTAGGGTTAATG-TCATCTAG-
3′; p53, (F) 5′-AGAGGAAGCCCTCCAAGTGTCA-3′ AND (R) 5′-ATAGT
GGTATAGTCGGAG-3′. GAPDH, (F) 5′-AACCCATCACCATCTTCCAG-
GAGC-3′ and (R) 5′-CACAGTCTTCTGAGTGGCAGTGAT-3′.
Nuclear extract preparation and electrophoretic mobility shift assays
(EMSAs)
Nuclear extracts were prepared using RL34 cells following the
standard protocol, with modiﬁcations. Brieﬂy, cells were treated
with reagents and washed with cold PBS, suspended in NP-40
buffer (10 mM HEPES (pH 7.6)/3 mM MgCl2/40 mM KCl/2 mM
DTT/5% glycerol/0.5% (v/v) NP-40/10 mg/ml aprotinin/10 mg/ml
leupeptin/0.5 mM PMSF) and lysed by pipetting. Following
incubation for 5 min on ice, the samples were centrifuged, and the
supernatants were collected as the cytosol fraction. The
pellets were washed with NP-40 buffer twice, resuspended in high
salt buffer (10 mM HEPES (pH 7.9)/0.1 mM EGTA/420 mM NaCl/
0.5 mM DTT/1.5 mM MgCl2/0.5 mM PMSF/25% (v/v) glycerol),
and incubated for 30 min at 4 °C with rotation. After centrifugation
the supernatants were collected as the nuclear fraction.
For EMSA, we used the 5′ GCAGAGGGCGGTGCAGCTCT 3′
oligonucleotide as a distal GC-rich element and 5′-AAAGC
TGGGGGGGTGGGGGGGTGGGGAAAG-3′ oligonucleotide as a
proximal GC-rich element. Nuclear extracts (10 mg protein) were
preincubated with 2 mg of poly(dIdC) in 20 ml containing 20 mM
HEPES-HCl (pH 7.9), 100 mM KCl, 4 mM MgCl2, 0.5 mM EDTA,
0.5 mM PMSF, 10% glycerol for 15 min on ice before the addition of
a 32P-radiolabeled oligonucleotide probe (4104 cpm). The in-
cubation was continued for 20 min at room temperature. The
samples were loaded onto a 4.5% polyacrylamide gel and electro-
phoresed at 20 mA in 0.5 Tris-borate–EDTA buffer (450 mM
Tris-borate (pH 8.0), and 1 mM EDTA) containing 2.5% glycerol.
The gel was dried and exposed to an imaging plate and then
analyzed by BAS2500 (Fuji Film Co, Japan). For supershift analysis,
2 mg of speciﬁc antibodies to Sp1 was added to the reaction mix-
ture for 1 h on ice before the addition of a radiolabeled probe.
Immunoﬂuorescence histochemistry
Cells were grown on coverstrips in a 24-well plate and then
treated with the reagent at the indicated times. The cells were
washed with cold PBS two times and ﬁxed with 100% cold me-
thanol for 20 min at 20 °C. The cells were then washed three
times with PBS for 5 min, permeabilized with 0.5% Triton X-100 in
PBS for 15 min, and washed three times with PBS (15 min each).
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overnight for block nonspeciﬁc binding. Following washing with
TTBS three times for 5 min, the coverstrips were incubated in TTBS
containing anti-Sp1 antibodies for 1 h at room temperature. They
were then washed with TTBS three times for 5 min and further
incubated with TTBS containing anti-rabbit IgG-labeled FITC
(Dako) for 1 h at room temperature. The coverstrips were then
washed with TTBS three times for 10 min each and mounted.
Images were all viewed using a confocal image microscope
(BioRad).p53 
0 0.5 1 3 
- MG132 
0 0.5 1 3 
 + MG132 
Fig. 2. Proteasome-dependent down-regulation of p53 is involved in the Cox-2
expression. (A) Effect of p53 antisense oligonucleotides on the expression of Cox-2
mRNA (left) and protein (right). Indicated doses of antisense oligonucleotides were
transfected for 48 h in RL34 cells, and whole cell lysates and total RNA were then
prepared for the analysis of p53 and Cox-2 protein levels and their mRNA levels,
respectively. (B) Effect of a speciﬁc proteasome inhibitor on the HNE-induced
down-regulation of p53. RL34 cells were pretreated with 1 mM MG132 and then
treated with 25 mM HNE for the indicated times.Results
Inverse correlation between Cox-2 and p53 expression levels in re-
sponse to HNE
To examine whether the HNE-induced Cox-2 expression was
mechanistically linked to the p53 expression, changes in Cox-2
and p53 expression levels in response to HNE were analyzed. As
shown in Fig. 1, HNE enhanced Cox-2 protein expression in a time-
dependent manner. HNE induced a large and transient induction
of Cox-2 that peaked at 3 h followed by a gradual decline to the
control level after 24 h. Unlike Cox-2, Cox-1 expression levels re-
mained unchanged in response to the HNE-induced stress (data
not shown). In contrast, the p53 protein levels were signiﬁcantly
reduced during the ﬁrst 3 h of the HNE treatment; however, the
protein level of p53 thereafter began to recover and increased to
over the basal level after 6 h of treatment. There was no apparent
change in the p53 mRNA levels in response to the HNE treatment
(data not shown). These data suggest the possibility that the Cox-2
protein level may be inversely correlated with the protein level of
p53.
Proteasome-dependent down-regulation of p53 is involved in the
Cox-2 expression
The hypothesis that p53 might be negatively correlated with
Cox-2 expression was examined by the down-regulation of p53Cox-2
p53
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Fig. 1. Inverse correlation between Cox-2 and p53 expression levels in response to
HNE. Induction of Cox-2 and p53 protein expressions in RL34 cells exposed to HNE.
RL34 cells were treated with 25 mM HNE for different time intervals as indicated.
Whole cell lysates (25 mg) were subjected to immunoblot analysis for detection of
Cox-2 and p53. Relative intensities of Cox-2 and p53 proteins were estimated by
comparing the intensity of basal level of p53.using antisense oligonucleotides against p53. the p53 antisense
signiﬁcantly enhanced the expression of Cox-2 mRNA and protein
(Fig. 2A). The observation (Fig. 2B) that a speciﬁc proteasome in-
hibitor, MG132, signiﬁcantly suppressed the HNE-induced down-
regulation of p53 suggests that the proteasome should be re-
sponsible for the rapid reduction of p53 levels observed during the
ﬁrst 3 h of the HNE treatment. This is consistent with the fact that
rapid demise of p53 is largely achieved through the ubiquitin/
proteasome-dependent protein degradation pathway [12].
HNE stimulates dissociation of a p53–Sp1 heterocomplex
p53 regulates gene expression through binding to the con-
sensus element within the promoter region. However, the rat Cox-
2 promoter region has no putative p53-binding elements. This
suggests the possibility that p53 directly binds to and acts on
several cellular proteins, such as mdm2, SV40 T antigens, TATA
binding proteins, and Sp1 that have been shown to interact with
p53 [9,29]. In the present study, we focused on Sp1, because a
minimal promoter region required for the basal transcription of
the human Cox-2 gene contains GC-rich proximal sequences that
are speciﬁcally bound by Sp1 [30]. Indeed, several lines of evi-
dence have been reported to indicate molecular cross-talk be-
tween Sp1 and p53, including Sp1/p53-associated reciprocal [31],
synergistic and cooperative regulation of target gene transcription
[32,33]. To examine the functional interaction of p53 with Sp1, we
ﬁrst examined the formation of a p53–Sp1 heterocomplex in the
cells exposed to HNE. As shown in Fig. 3A, the immunoprecipita-
tion with an antibody to p53 or Sp1 followed by immunoblot
analysis with the anti-Sp1 antibody revealed the presence of p53–
Sp1 complexes in control and their dissociation by treatment with
HNE. The HNE-induced dissociation of p53–Sp1 complexes was
also conﬁrmed by immunoprecipitation with an anti-Sp1 antibody
followed by immunoblot analysis with the anti-p53 antibody
(Fig. 3B). Moreover, HNE-induced dissociation of p53–Sp1 com-
plexes was accompanied by nuclear translocation of Sp1 (Fig. 3C).
These data indicate that p53 associates with Sp1 to an appreciable
extent and that HNE enhances the dissociation of the p53–Sp1
complexes.
AB
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p53
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Fig. 3. HNE stimulates dissociation of a p53–Sp1 heterocomplex. (A) Im-
munoprecipitation with an antibody to p53 or Sp1 followed by immunoblot ana-
lysis with the anti-Sp1 antibody. (B) Immunoprecipitation with the anti-Sp1 anti-
body followed by immunoblot analysis with the anti-p53 antibody. In A and B, RL34
cells were treated with 25 mM HNE for 1 h. Immunoprecipitation followed by im-
munoblot analysis was performed as described in Experimental Procedures section.
(C) Nuclear translocation of Sp1. RL34 cells were treated with 25 mM HNE for dif-
ferent time intervals as indicated. The cells were ﬁxed with cold methanol and
permeabilized with 0.5% Triton X-100/PBS and immunostained with the anti-Sp1
antibody. Images of the cellular immunoﬂuorescence were acquired using a con-
focal laser scanning microscope.
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To examine whether HNE-induced dissociation of p53–Sp1
complexes and nuclear translocation of Sp1 were accompanied by
activation of Sp1, we performed EMSAs using the oligonucleotide
containing the Sp1 consensus element as a probe. Probes were
described under Experimental Procedures section. As shown in
Fig. 4A, two major DNA–protein complexes were observed. HNE
treatment resulted in a time-dependent increase in the Sp1 DNA
binding activity. Approximately a 2.5-fold increase in the Sp1–DNA
binding activity was observed in the HNE-treated cells compared
to the control. An almost maximal increase in Sp1 binding activity
in response to HNE treatment was observed by 1 h, and these
responses persisted for at least 3 h. The addition of antibody di-
rected against Sp1 induced a supershift and a signiﬁcant reduction
in Sp1-dependent binding activity (Fig. 4B). Sp1 antibody mainly
eliminated the upper complex. Although Sp1 abundance has been
implicated in changes in Sp1 transcriptional activity [34], we did
not see any changes in Sp1 level during the incubation periods
(data not shown). Because Cox-2 gene expression is also tran-
scriptionally regulated via the transactivation factor NF-κB p65 inhuman vascular endothelial cells [35], we investigated the in-
volvement of NF-κB in the HNE-stimulated up-regulation of Cox-2.
However, activation of NF-κB was not observed by EMSAs and by
immunohistochemistry analyses (data not shown). Thus, Sp1 is
likely to be involved in the HNE-stimulated gene expression of
Cox-2. Taken together, down-regulation of p53 followed by the
activation of transcription factor Sp1 was suggested to be involved
in the HNE-induced Cox-2 gene expression.
Cox-2 overexpression causes down-regulation of a proteasome
subunit
Although a causal role for Cox-2 has been proposed, mechan-
isms by which Cox-2 function contributes to the pathogenesis of
hyperplastic disease are not well deﬁned. As shown in Fig. 1, the
recovery of p53 protein levels after 3 h of incubation seemed to be
associated with the decrease in the protein level of Cox-2. To ex-
amine if there is any correlation between Cox-2 and p53 protein
levels, we established the Cox-2-overexpressing derivatives of
RL34 cells by stable transfection with Cox-2 cDNA. The Cox-2 ex-
pression vector (pcCox-2) was introduced into RL34 cells and four
clones with resistance to G418 were selected. As a control, RL34
cells transfected with a control vector were similarly selected for
G418 resistance. Eventually, three Cox-2-overexpressed cells
(clone nos. 3, 8, 15) were isolated. As shown in Fig. 5, the Cox-2-
transfected clone (no. 8) demonstrated a readily detectable ex-
pression of the Cox-2 protein by immunoblot analysis (panel A)
and immunocytochemistry (panel B) with the anti-Cox-2 poly-
clonal antibody, whereas the control transfected cells did not.
Stable transfection of Cox-2 into RL34 cells yielded comparable
amounts of PGD2 (panel C), suggesting that the Cox-2 polypeptide
is enzymatically active.
To investigate the Cox-2-mediated change in gene expression,
microarray analysis was used to examine the expression proﬁle of
a large number of transcripts. As shown in Table 1, we observed
signiﬁcant up-regulation of acetylcholinesterase-associated col-
lagen, isopentenyl diphosphate–dimethylallyl diphosphate iso-
merase, and p38 MAPK genes. In addition, the expression of genes
involved in the phase II detoxiﬁcation response, such as glu-
tathione S-transferase Yb and Yc subunits, was also signiﬁcantly
up-regulated. Meanwhile, we observed signiﬁcant down-regula-
tion of proteasome subunits RC1 and RN3, transforming growth
factor beta-3, heat shock protein 27, apolipoprotein E, and pros-
tacyclin synthase (Table 2). Most notably, the proteasome RC1
subunit was dramatically down-regulated by 26-fold in the Cox-
2 overexpressed cells. To conﬁrm the microarray ﬁndings that the
proteasome RC1 mRNA was down-regulated in Cox-2-over-
expressed cells, RT-PCR was performed. As shown in Fig. 6, con-
sistent with the microarray results, the levels of proteasome sub-
units RC1 and RN3, apolipoprotein E, and prostacyclin synthase
were signiﬁcantly down-regulated in the Cox-2-overexpressed
cells. We determined whether prostanoid secretion by the Cox-2-
transfected cells is necessary for the down-regulation of protea-
some RC1 subunit caused by Cox-2. However, a series of Cox in-
hibitors, such as dexamethasone, nimesulide, ibuprofen, and
NS398, were inactive in the recovery of the proteasome RC1 sub-
unit in the Cox-2-overexpressed cells (Supplementary data, Fig.
S1), suggesting the prostanoid-independent down-regulation of
the proteasome subunit.
Enhanced accumulation of p53 and ubiquitinated proteins in the Cox-
2-overexpressed cells
Accompanied by the down-regulation of the proteasome
subunit, the proteasome activities (chymotrypsin-like, trypsin-
like, and peptidylglutamyl peptide hydrolase activities) were
A B
0 45 1
Time after treatment
10 20 30 2 3 6 10 16 24
(min) (h)
0 45 1
Time after treatment
10 20 30 2 3 6 101624
(min) (h)
0
+ anti-Sp1- anti-Sp1
Fig. 4. Activation of Sp1 by HNE. EMSAs were performed using the oligonucleotide containing the Sp1 consensus element as a probe. (A) Time-dependent activation of Sp1.
Nuclear extracts from RL34 cells treated or untreated with 25 mM HNE for the indicated times were incubated with the 32P-labeled Sp1 oligonucleotides and separated by
4.5% acrylamide gel electrophoresis. (B) Nuclear extracts were prepared from RL34 cells treated with 25 mM HNE for the indicated times, preincubated with or without Sp1
antibody prior to the addition of the radiolabeled probe and separated by 4.5% acrylamide gel electrophoresis.
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(Fig. 7A). Because proteasome is responsible for the majority of
cellular proteolysis in eukaryotic cells and contributes to control-
ling the intracellular levels of a variety of short-lived proteins [36–
38], it was anticipated that this Cox-2-mediated dysfunction of
proteasome might inﬂuence the turnover of proteasome sub-
strates. Substrates of proteasome include a number of cell reg-
ulatory molecules, such as p53. Indeed, we observed that the basal
level of p53 in Cox-2-overexpressed cells was signiﬁcantly higher
than that in the empty-vector transfected control cells (Fig. 7B). No
signiﬁcant morphological and cell proliferative difference in COX-2
overexpressing cells compared to control cells were observed. The
functional impact of Cox-2 overexpression on proteasome activity
was also evaluated by the accumulation of ubiquitinated proteins
in response to HNE. As shown in Fig. 7C, a steady-state level of
ubiquitinated proteins was found to be higher in the Cox-2-over-
expressed cells than in the control cells. Moreover, the HNE-in-
duced accumulation of ubiquitinated proteins was signiﬁcantly
enhanced by the Cox-2 overexpression.
Sensitivity of Cox-2-overexpressed cells to electrophiles
Finally, we examined the effect of Cox-2 overexpression on the
cytotoxicity of electrophiles. One control and three Cox-2-trans-
fected cells (clone nos. 3, 8, and 15) were examined by MTT assay
for sensitivity to the cytotoxicity induced by exposure to HNE,
showing that HNE (50 mM) resulted in a decrease in the MTT re-
duction levels to 63% of the basal levels in vector control cells and
to 10% of the basal levels in Cox-2-overexpressed cells after 9 h
(Fig. 8, panels A and B). Cytotoxicity induced by other electro-
philes, tert-butylhydroquinone and diethylmaleate, was alsoenhanced in the Cox-2-overexpressed cells compared with the
control cells (Fig. 8C). These results suggest that the proteasome
dysfunction mediated by the Cox-2 overproduction inﬂuences
cellular integrity and makes the cells sensitive to electrophiles.Discussion
Under oxidative stress, HNE is believed to be produced in re-
latively high amounts in vivo, reaching concentrations of 10 mM to
5 mM in response to oxidative insults [21]. Moreover, HNE, which
has an electrophilic property, attacks many molecules such as
proteins and nucleotides and forms adducts with them, thus
causing dysfunction of the target molecules. In particular, the re-
action between HNE and proteins has been well established. HNE
has the ability to form adducts with proteins by interacting with
either the sulfhydryl groups of cysteine or the amino groups of
lysine and histidine [39]. By immunohistochemical analysis, HNE–
protein adducts have been detected in types of disorder foci from
liver disease to neuronal disease [39]. Interestingly, Cox-2 ex-
pression or prostaglandin overproduction is also seen in several of
the same disease foci, such as atherosclerosis and Alzheimer's
disease [40,41]. In the liver, it is known that oxidative stress is
increased with alcohol feeding and is accompanied by lipid per-
oxidation products such as HNE [42]. Moreover, in an alcohol-fed
rat, which is a model of alcoholic liver disease, alcohol over-intake
increases HNE-modiﬁed protein formation and is associated with
the Cox-2 and proinﬂammatory cytokine TNF-α expression
[23,43]. These ﬁndings suggest the possibility that lipid perox-
idation products may be involved in the up-regulation of the
prostaglandin biosynthesis.
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Fig. 5. Preparation of Cox-2-overexpressing derivatives of RL34 cells. The Cox-2
expression vector (pcCox-2) was introduced into RL34 cells, and three clones (clone
nos. 3, 8, 15) with resistance to G418 were selected. As a control, RL34 cells trans-
fected with a control vector and were similarly selected for G418 resistance. The
levels of Cox-2 protein in the control transfected cells and the Cox-2-overexpressed
cells (clone no. 8) were examined by immunoblot analysis (A) and immuno-
cytochemistry (B) with the anti-Cox-2 monoclonal antibody. (C) The levels of PGD2 in
the control transfected cells and the Cox-2-overexpressed cells (clone no. 8).
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taglandin synthesis play an important role in the promotion of
various proliferative diseases including cancer. It is well docu-
mented that Cox-2 can be induced by growth factors and cyto-
kines, inﬂammatory stimuli and tumor promoters [44–47]. Recent
studies have provided evidence that oxidative stresses as well as
DNA-damaging agents, including ionizing radiation, can induce
Cox-2 expression [48–50]. However, the mechanism of induction
of Cox-2 in response to oxidative stress or DNA damage remains
unknown. In our previous study, based on the experimental evi-
dence [23] that oxidative stress is closely associated with the up-
regulation of Cox-2, we evaluated the effect of the oxidized fatty
acid metabolites on Cox-2 induction in rat liver epithelial RL34
cells and found that, among the oxidized fatty acid metabolites
tested, only HNE showed the inducibility of Cox-2 expression [24].
In addition, we investigated the molecular mechanism underlying
the Cox-2 induction by HNE and established that the p38 mitogen-
activated protein kinase pathway, which exerts its function by
increasing the stability of Cox-2 mRNA, plays a key role in the
mechanism of HNE-induced Cox-2 expression in RL34 cells [25]. In
the present study, to investigate transcriptional regulation of the
Cox-2 gene in response to HNE, we examined whether the HNE-
induced Cox-2 was mechanistically linked to the p53 expressionand found that the Cox-2 levels were inversely correlated with
the p53 levels (Fig. 1). In addition, the down-regulation of p53
with the antisense oligonucleotides against p53 signiﬁcantly
enhanced the expression of Cox-2 mRNA and protein (Fig. 2A).
These observations are important for several reasons. For example,
suppression of Cox-2 expression by p53 can explain why levels
of Cox-2 protein are undetectable in normal epithelial cells and,
by contrast, why mutations of p53 may contribute to the
increased expression of Cox-2 that is observed in malignant tissues
[51–55].
p53 regulates gene expression through binding to the con-
sensus element within the promoter region. However, it is also
known that p53 suppresses a variety of promoters that contain
TATA elements [56–58]. This suppression is thought to occur
through direct interaction with components of the basal tran-
scription machinery, such as TAF70, TFIIH, and TATA binding
proteins. On the other hand, based on the following observations,
we hypothesized that Sp1, a general transcription factor that is
involved in various inducible and constitutive gene expressions, is
also involved in the induction of Cox-2 in response to HNE. (i) p53
suppresses various gene expressions through preventing Sp1 ac-
tivity [59], (ii) The rat Cox-2 promoter region has no putative p53-
binding elements, and a minimal promoter region required for the
basal transcription of the human Cox-2 gene has been demon-
strated to contain GC-rich proximal sequences that are speciﬁcally
bound by Sp1 [60], and (iii) p53 negatively regulates Sp1 through
the formation of a p53–Sp1 heterocomplex [61,62]. Indeed, the
immunoprecipitation experiments indicated that p53 bound to
Sp1 in intact cells under normal conditions and that HNE stimuli
elicited the dissociation (Fig. 3, panels A and B). It was also ob-
served that the dissociation of p53–Sp1 complexes was accom-
panied by the nuclear translocation of Sp1 (Fig. 3C). To examine
whether HNE-induced dissociation of p53–Sp1 complexes and
nuclear translocation of Sp1 were accompanied by activation of
Sp1, we performed EMSAs using the oligonucleotide containing
the Sp1 consensus element as a probe and observed that HNE
treatment resulted in a time-dependent increase in the Sp1 DNA
binding activity (Fig. 4). Although the regulatory mechanism of
dissociation of p53–Sp1 complex remains unclear, the involve-
ment of a phosphatidylinositol 3-kinase pathway, which induces
p53 degradation through mdm2 phosphorylation [63–65], may
not be unlikely. This possibility is supported by our ﬁnding that
HNE activates phosphatidylinositol 3-kinase/AKT pathway in vas-
cular smooth muscle cells [66] and our observation that wort-
mannin, a speciﬁc inhibitor of phosphatidylinositol 3-kinase, sig-
niﬁcantly inhibited the Cox-2 expression (T. Kumagai and K.
Uchida, unpublished data). Taken together, it is hypothesized that
down-regulation of p53 followed by the activation of a transcrip-
tion factor Sp1 may be involved in the HNE-induced Cox-2 gene
expression (Fig. 9).
Aberrant up-regulation of Cox-2 expression is increasingly
implicated in the pathogenesis of epithelial cell carcinomas such
as human colorectal adenocarcinomas and colorectal tumors [67].
Previous studies in rat medullary interstitial cells have shown that
Cox-2 overexpression leads to a number of effects that could be
associated with tumorigenesis: increased adhesion to extracellular
matrix proteins, inhibition of butyrate-induced apoptosis, de-
creased expression of both E-cadherin and transforming growth
factor 2 receptor, and stimulation of Bcl-2 protein expression [68].
Cox-2-expressing cells also produce high levels of angiogenic
factors that stimulate angiogenesis [69]. It has also been shown
that the sustained presence of Cox-2 is involved in the regulation
of cell cycle arrest [70]. Indeed, treatment of vascular endothelial
cells with the cytokine interleukin-1 or tumor promoter PMA re-
sults in a concomitant increase in Cox-2 expression and inhibition
of cell growth [71].
Table 1
Cox-2-inducible genes in rat liver epithelial RL34 cells.
Accession no. Gene name Fold
AF007583 Rattus norvegicus acetylcholinesterase-associated collagen (COLQ) mRNA, complete cds 2.04
AF003835 Rattus norvegicus isopentenyl diphosphate–dimethylallyl diphosphate isomerase mRNA, complete cds 1.98
RNU73142 Rattus norvegicus p38 mitogen activated protein kinase mRNA, complete cds 1.84
AF025506 Rattus norvegicus prenylated rab acceptor 1 (PRA1) mRNA, complete cds 1.78
AF076183 Rattus norvegicus cytosolic sorting protein PACS-1a (PACS-1) mRNA, complete cds 1.69
RATSIRR2 RATSIRR2 Rat mRNA for sIRR-2 (insulin receptor-related receptor alternatively spliced product), complete cds 1.67
RNCF6M Rattus norvegicus mRNA for coupling factor 6 of mitochondrial ATP synthase complex 1.67
AF062594 Rattus norvegicus nucleosome assembly protein mRNA, complete cds 1.66
RATRBP6A Rat insulin-like growth factor binding protein (rIGFBP-6) mRNA, complete cds 1.62
AB011679 Rattus norvegicus mRNA for class I beta-tubulin, complete cds 1.60
RATFN3M1 L00191cds#1 RATFN3M1 Rat ﬁbronectin (cell-, heparin-, and ﬁbrin-binding domains) gene encoding three ﬁbronectin mRNAs, exons 1, 2, 3 1.57
RATIP3R3X Rat inositol trisphosphate receptor subtype 3 (IP3R-3) mRNA, complete cds 1.55
RATGSTYC Rat liver glutathione S-transferase Yc subunit mRNA, complete cds 1.52
AB005549 Rattus norvegicus mRNA for atypical PKC speciﬁc binding protein, complete cds 1.51
RATCSBP D17711cds RATCSBP Rat mRNA for dC-stretch binding protein (CSBP), complete cds 1.49
RNU95178 Rattus norvegicus DOC-2p59 isoform mRNA, complete cds 1.49
RATPRORR12 RATPRORR12 Rat mRNA for proteasome subunit R-RING12, complete cds 1.49
RNGSTYBR X04229cds RNGSTYBR Rat mRNA for glutathione S-transferase (GST) Y(b) subunit (EC 2.5.1.18) 1.45
AB011532 Rattus norvegicus mRNA for MEGF6, complete cds 1.44
RATBTG1H Rattus norvegicus anti-proliferative factor (BTG1) mRNA, complete cds 1.44
AF031878 Rattus norvegicus peripherin mRNA, complete cds 1.44
RATTYRPHOS RATTYRPHOS Rat protein tyrosine phosphatase mRNA, complete cds 1.43
RATESP1A RATESP1A Rattus rattus R-esp1 mRNA, complete cds 1.42
RATRIP M24542cds RATRIP Rat Rieske iron–sulfur protein mRNA, complete cds 1.42
RRRPL21 X15216 cds RRRPL21 Rattus rattus mRNA for ribosomal protein L21 1.41
The top 25 genes that are up-regulated in the Cox-2-overexpressed cells are shown in the order of the values of the ratio of expression levels between control and Cox-2-
overexpressed cells.
Table 2
Cox-2-repressed genes in rat liver epithelial RL34 cells.
Accession no. Gene name Fold
RATPSRC1 RATPSRC1 Rat mRNA for proteasome subunit RC1 0.04
RRU03491 Rattus norvegicus Wistar transforming growth factor beta-3 mRNA, complete cds 0.28
RATHSP27A M86389cds RATHSP27A Rat heat shock protein (Hsp27) mRNA, complete cds 0.36
RATMEP Rat metalloendopeptidase mRNA, complete cds 0.42
RNU53855 Rattus norvegicus prostacyclin synthase (ratpgis) mRNA, complete cds 0.44
RRU07619 Rattus norvegicus Sprague-Dawley tissue factor protein mRNA, complete cds 0.45
AF045564 Rattus norvegicus development-related protein mRNA, complete cds 0.45
AB014722 Rattus norvegicus mRNA for rSALT-1(806), complete cds 0.46
AF016047 Rattus norvegicus platelet-activating factor acetylhydrolase alpha 1 subunit (PAF-AH alpha 1) gene, complete cds 0.47
RNU34932 Rattus norvegicus Fos-related antigen mRNA, complete cds 0.47
AF057564 Rattus norvegicus putative retrovirus-related gag protein mRNA, complete cds 0.48
AF051155 Rattus norvegicus G beta-like protein GBL mRNA, complete cds 0.48
RNU18729 Rattus norvegicus cytochrome b558 alpha-subunit mRNA, complete cds 0.51
AB003991 rat mRNA for SNAP-25A, complete cds. 0.51
S76054 cytokeratin-8 [rats, prostatic epithelia, mRNA, 1747 nt] 0.53
RATSCPIIX Rat voltage-dependent sodium channel type II protein gene, complete cds. 0.60
RNU19893 Rattus norvegicus alpha actinin mRNA, complete cds 0.61
RNAPOEG Rat gene for apolipoprotein E. 0.61
RNEP2GL X56327cds RNEP2GL Rattus norvegicus epsilon 2 globin gene 0.63
RATBCCAPA Rattus norvegicus beta'-chain clathrin associated protein complex AP-1 mRNA, complete cds 0.64
RATCYP2A1 M33312cds RATCYP2A1 Rat hepatic steroid hydroxylase IIA1 (CYP2A1) gene, complete cds 0.64
D89514 Rattus norvegicus mRNA for 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase, complete cds 0.64
AF104399 Rattus norvegicus melanocyte-speciﬁc gene 1 protein (msg1) mRNA, complete cds 0.65
S75280 Rattus sp. pre-mtHSP70 mRNA complete cds; nuclear gene for mitochondrial product 0.65
RATTRO2A Rat alpha-tropomyosin 2 mRNA, complete cds 0.66
RNGPXIMR X12367 cds RNGPXIMR Rattus norvegicus mRNA for glutathione peroxidase I 0.66
RRLENSABC X60351 cds RRLENSABC Rattus rattus mRNA for alpha B-crystallin (ocular lens tissue) 0.66
RATSERINE Rattus norvegicus serine protease gene, complete cds 0.67
RATCTTG Rat troponin T cardiac isoform gene, complete cds 0.67
RNU16253 Rattus norvegicus corticotropin-releasing factor receptor subtype 2 (CRF2R) mRNA, complete cds. 0.67
S78556 grp75¼75 kDa glucose regulated protein [rats, Sprague-Dawley, brain, mRNA, 3001 nt] 0.68
RATCRYAB Rat alpha-crystallin B chain mRNA, complete cds 0.68
RNU31880 Rattus norvegicus eIF-2B beta subunit mRNA, complete cds 0.69
AF074609 AF074609mRNA Rattus norvegicus MHC class I antigen (RT1.EC3) gene, complete cds 0.70
RATRN3 RATRN3 Rattus norvegicus proteasome RN3 subunit mRNA, complete cds 0.70
The top 35 genes that are down-regulated in the Cox-2-overexpressed cells are shown in the order of the values of the ratio of expression levels between control and Cox-2-
overexpressed cells.
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Fig. 6. Cox-2 overexpression causes down-regulation of a proteasome subunit.
Gene expression of proteasome subunits RC1 and RN3, apolipoprotein E, and
prostacyclin synthase in the control transfected cells and the Cox-2-overexpressed
cells (clone no. 8) was analyzed by RT-PCR.
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Fig. 7. Enhanced accumulation of p53 and ubiquitinated proteins in the Cox-2-
overexpressed cells. (A) Effect of Cox-2 overexpression on proteasome activity in
RL34 cells. Bars: hatched bars, control transfected cells; closed bars, Cox-2-over-
expressed cells. The results shown are the mean7S.E.M. of 3 independent ex-
periments. The proteasome activities were measured using the ﬂuoropeptides,
s-LLVY-MCA, for the chymotrypsin-like activity, Boc-LSTR-MCA for the trypsin-like
activity, and Z-LLE-βNA for the peptidylglutamyl peptide hydrolase activity, as
proteolytic substrates. The results shown are the mean7S.E.M. of 3 independent
experiments. (B) HNE-induced accumulation of p53 in the control transfected cells
and the Cox-2-overexpressed cells (clone no. 8). (C) HNE-induced accumulation of
ubiquitin–protein conjugates in the control transfected cells and the Cox-2-over-
expressed cells (clone no. 8). In panels B and C, both cells were incubated with
25 mM HNE at 37 °C.
T. Kumagai et al. / Redox Biology 4 (2015) 74–8682The present study utilized gene expression proﬁling to assess
thousands of genes to obtain a more detailed understanding of the
molecular programs utilized by Cox-2-overexpressed cells. One
important outcome from this study includes the identiﬁcation of a
link between sustained overexpression of Cox-2 and proteasome
dysfunction. Proteasome is a large multisubunit protease complex
that selectively degrades intracellular proteins [72–74]. Most of
the proteins removed by these proteases are tagged for destruction
by ubiquitination. Proteasome has a role to play in controlling
cellular processes, such as metabolism and the cell cycle, through
signal-mediated proteolysis of key enzymes and regulatory pro-
teins. It also operates in the stress response by removing abnormal
proteins and in the immune response by generating antigenic
peptides. A decreased capacity for protein degradation is related to
several degenerative diseases, such as Parkinson's disease, Alz-
heimer's disease, and amyotrophic lateral sclerosis, in which ac-
cumulation of abnormal polypeptides within cells leads to the
death of neurons, as well as diabetes and atherosclerosis. An al-
tered ubiquitin–proteasome system and reduced proteasome ac-
tivity are associated with some of these diseases [75–78]. In the
present study, Cox-2 overexpression in RL34 cells resulted in
speciﬁc down-regulation of the proteasome subunit RC1 (Table 2
and Fig. 6). The proteasome dysfunction mediated by the Cox-2
overproduction was associated with (i) a moderate reduction of
the proteasome activities (chymotrypsin-like, trypsin-like, and
peptidylglutamyl peptide hydrolase activities) (Fig. 7A), (ii) the
accumulation of detrimental proteins, such as p53 (B) and ubi-
quitinated proteins (C), and (iii) enhanced sensitivity toward
electrophiles (Fig. 8). The observation that the protein level of p53
began to increase after the Cox-2 level reached a maximum at 3 h
(Fig. 1A) suggests that the accumulation of p53 may be associatedwith the down-regulation of Cox-2 through binding to Sp1
(Fig. 10). Alternatively, based on our previous observation that
15-deoxy-Δ12,14-prostaglandin J2, a metabolite of PGD2, inactivates
proteasome through covalent modiﬁcation [79], the decrease in
the proteasome activity observed in this study may also be caused
by the PG metabolites.
It has been shown that the overall structure of the proteasome
RCl is almost identical to that of Ring10, whose gene is located in
the class II region of the human MHC gene cluster [80]. In the
meantime, it also appeared that the ability of Cox-2 to induce
down-regulation of the proteasome subunit RC1 was independent
of prostanoid secretion (Supplementary data, Fig. S1). This pros-
tanoid-independent effect of Cox-2 is not unique to the
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Fig. 8. Sensitivity of Cox-2-overexpressed cells to electrophiles. (A) HNE cytotoxicity to the control and Cox-2-overexpressed cells. One control and three Cox-2-transfected
cells (clone nos. 3, 8, and 15) were examined by MTT assay for sensitivity to HNE (50 mM). (B) Time-dependent reduction of cell viability induced by HNE (50 mM) in the
control transfected cells and the Cox-2-overexpressed cells (clone no. 8). (C) Electrophile cytotoxicity to the control and Cox-2-overexpressed cells. The control transfected
cells and the Cox-2-overexpressed cells (clone no. 8) were examined by MTT assay for sensitivity to HNE (50 or 75 mM), butylhydroquinone (50 or 100 mM), and diethyl-
maleimide (500 or 750 mM) for 24 h.
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Fig. 9. Model for mechanisms by which HNE up-regulates Cox-2. HNE stabilizes Cox-2 mRNA through the p38 MAPK signaling pathway, leading to the up-regulation of Cox-
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T. Kumagai et al. / Redox Biology 4 (2015) 74–86 83
HNE
p38  
p53/Sp1
p53 
Cox-2 
Proteasome 
Fig. 10. Regulatory mechanism of Cox-2 gene expression mediated by proteasome
dysfunction followed by p53 up-regulation.
T. Kumagai et al. / Redox Biology 4 (2015) 74–8684proteasome subunit. Indeed, it has previously been shown that
interleukin-1 and PMA-induced endothelial cell growth arrest is
not reversed by nonsteroidal anti-inﬂammatory drugs that block
prostanoid synthesis [71] and that neither NS-398 (a Cox-2-spe-
ciﬁc inhibitor) nor indomethacin could reverse the effect of Cox-2
overexpression on cell cycle progression [70]. Although the de-
tailed mechanisms by which Cox-2 overexpression down-regu-
lated the proteasome subunit remain unclear, interaction of the
Cox-2 polypeptide with regulatory protein(s) on gene expression
of the proteasome subunit may not be unlikely. Indeed, Cox-2 was
shown to bind to an apoptosis regulatory protein nucleobindin
[81]. Nevertheless, data in this report show unequivocally that
Cox-2 overexpression induces proteasome dysfunction by an un-
characterized nonprostanoid-dependent signaling pathway. Fur-
ther studies are required to deﬁne at a molecular level this novel
mechanism of Cox-2 function and to assess its physiological
relevance.Acknowledgments
We thank Ms. Yuki Hondoh for her excellent editorial support.
This work was supported in part by COST CM 1001; Grants-in-Aid
for Scientiﬁc Research (numbers: 21248016 and 24658122),
Grants-in-Aid for Scientiﬁc Research on Innovative Areas (Re-
search in a Proposed Area) (number: 20117007), JST A-step pro-
gram (number: AS242Z01310Q), and JST PRESTO program (number:
10604) from the Ministry of Education, Culture, Sports, Science, and
Technology of Japan (MEXT).Appendix A. Supplementary data
The supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.redox.2014.11.011.References
[1] W.L. Smith, R.M. Garavito, D.L. DeWitt, Prostaglandin endoperoxide H syn-
thases (cyclooxygenases)-1 and 2, Journal of Biological Chemistry 271 (52)
(1996) 33157–33160. http://dx.doi.org/10.1074/jbc.271.52.33157 8969167.
[2] K. Yamamoto, T. Arakawa, N. Ueda, S. Yamamoto, Transcriptional roles of nu-
clear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosisfactor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells,
Journal of Biological Chemistry 270 (52) (1995) 31315–31320 8537402.
[3] R.P. Ryseck, C. Raynoschek, H. Macdonald-Bravo, K. Dorfman, M.G. Mattéi,
R. Bravo, Identiﬁcation of an immediate early gene, pghs-B, whose protein
product has prostaglandin synthase/cyclooxygenase activity, Cell Growth &
Dfferentiation 3 (7) (1992) 443–450 1419907.
[4] K. Yamagata, K.I. Andreasson, W.E. Kaufmann, C.A. Barnes, P.F. Worley, Ex-
pression of a mitogen-inducible cyclooxygenase in brain neurons: regulation
by synaptic activity and glucocorticoids, Neuron 11 (2) (1993) 371–386. http:
//dx.doi.org/10.1016/0896-6273(93)90192-T 8352945.
[5] R. Newton, J. Seybold, L.M. Kuitert, M. Bergmann, P.J. Barnes, Repression of
cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by
transcriptional and post-transcriptional mechanisms involving loss of poly-
adenylated mRNA, Journal of Biological Chemistry 273 (48) (1998)
32312–32321. http://dx.doi.org/10.1074/jbc.273.48.32312 9822711.
[6] J.L. Dean, M. Brook, A.R. Clark, J. Saklatvala, p38 mitogen-activated protein
kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipo-
polysaccharide-treated human monocytes, Journal of Biological Chemistry 274
(1) (1999) 264–269. http://dx.doi.org/10.1074/jbc.274.1.264 9867839.
[7] K. Subbaramaiah, N. Altorki, W.J. Chung, J.R. Mestre, A. Sampat, A.
J. Dannenberg, Inhibition of cyclooxygenase-2 gene expression by p53, Journal
of Biological Chemistry 274 (16) (1999) 10911–10915. http://dx.doi.org/
10.1074/jbc.274.16.10911 10196169.
[8] N.V. Chandrasekharan, H. Dai, K.L. Roos, N.K. Evanson, J. Tomsik, T.S. Elton, D.
L. Simmons, COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen
and other analgesic/antipyretic drugs: cloning, structure, and expression,
Proceedings of the National Academy of Sciences of the United States of
America 99 (2002) 13926–13931. http://dx.doi.org/10.1073/pnas.162468699
12242329.
[9] A.J. Levine, p53, the cellular gatekeeper for growth and division, Cell 88 (3)
(1997) 323–331. http://dx.doi.org/10.1016/S0092-8674(00)81871-1 9039259.
[10] R. Hansen, M. Oren, p53; from inductive signal to cellular effect, Current
Opinion in Genetics & Development 7 (1) (1997) 46–51. http://dx.doi.org/
10.1016/S0959-437X(97)80108-6 9024633.
[11] M.L. Agarwal, W.R. Taylor, M.V. Chernov, O.B. Chernova, G.R. Stark, The p53
network, Journal of Biological Chemistry 273 (1) (1998) 1–4. http://dx.doi.org/
10.1074/jbc.273.1.1 9417035.
[12] M. Oren, Regulation of the p53 tumor suppressor protein, Journal of Biological
Chemistry 274 (51) (1999) 36031–36034. http://dx.doi.org/10.1074/
jbc.274.51.36031 10593882.
[13] W.S. El-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin,
W.E. Mercer, K.W. Kinzler, B. Vogelstein, WAF1, a potential mediator of p53
tumor suppression, Cell 75 (4) (1993) 817–825. http://dx.doi.org/10.1016/
0092-8674(93)90500-P 8242752.
[14] Y. Barak, T. Juven, R. Haffner, M. Oren, mdm2 expression is induced by wild
type p53 activity, EMBO Journal 12 (2) (1993) 461–468 8440237.
[15] T. Miyashita, S. Krajewski, M. Krajewska, H.G. Wang, H.K. Lin, D.A. Liebermann,
B. Hoffman, J.C. Reed, Tumor suppressor p53 is a regulator of bcl-2 and bax
gene expression in vitro and in vivo, Oncogene 9 (6) (1994) 1799–1805
8183579.
[16] T. Miyashita, J.C. Reed, Tumor suppressor p53 is a direct transcriptional acti-
vator of the human bax gene, Cell 80 (2) (1995) 293–299. http://dx.doi.org/
10.1016/0092-8674(95)90412-3 7834749.
[17] Q. Wang, G.P. Zambetti, D.P. Suttle, Inhibition of DNA topoisomerase II alpha
gene expression by the p53 tumor suppressor, Molecular and Cellular Biology
17 (1) (1997) 389–397 8972219.
[18] Q. Wang, W.T. Beck, Transcriptional suppression of multidrug resistance-as-
sociated protein (MRP) gene expression by wild-type p53, Cancer Research 58
(24) (1998) 5762–5769 9865734.
[19] B.C. Ding, J.R. Whetstine, T.L. Witt, J.D. Schuetz, L.H. Matherly, Repression of
human reduced folate carrier gene expression by wild type p53, Journal of
Biological Chemistry 276 (12) (2001) 8713–8719. http://dx.doi.org/10.1074/jbc.
M005248200 11106643.
[20] B. Halliwell, J.M.C. Gutteridge, Free Radicals in Biology and Medicine, second
edition, Clarendon Press, Oxford, 1989.
[21] H. Esterbauer, R.J. Schaur, H. Zollner, Chemistry and biochemistry of 4-hy-
droxynonenal, malonaldehyde and related aldehydes, Free Radical Biology and
Medicine 11 (1) (1991) 81–128 1937131.
[22] K. Uchida, Role of reactive aldehyde in cardiovascular diseases, Free Radical
Biology and Medicine 28 (12) (2000) 1685–1696 10946210.
[23] A.A. Nanji, L. Miao, P. Thomas, A. Rahemtulla, S. Khwaja, S. Zhao, D. Peters, S.
R. Tahan, A.J. Dannenberg, Enhanced cyclooxygenase-2 gene expression in
alcoholic liver disease in the rat, Gastroenterology 112 (3) (1997) 943–951
9041257.
[24] T. Kumagai, Y. Kawamoto, Y. Nakamura, I. Hatayama, K. Satoh, T. Osawa,
K. Uchida, 4-Hydroxy-2-nonenal, the end product of lipid peroxidation, is a
speciﬁc inducer of cyclooxygenase-2 gene expression, Biochemical and Bio-
physical Research Communications 273 (2) (2000) 437–441. http://dx.doi.org/
10.1006/bbrc.2000.2967 10873624.
[25] T. Kumagai, Y. Nakamura, T. Osawa, K. Uchida, Role of p38 mitogen-activated
protein kinase in the 4-hydroxy-2-nonenal-induced cyclooxygenase-2 ex-
pression, Archives of Biochemistry and Biophysics 397 (2) (2002) 240–245.
http://dx.doi.org/10.1006/abbi.2001.2601 11795877.
[26] P.O. Brown, D. Botstein, Exploring the new world of the genome with DNA
microarrays, Nature Genetics 21 (1 Suppl.) (1999) 33–37. http://dx.doi.org/
10.1038/4462 9915498.
T. Kumagai et al. / Redox Biology 4 (2015) 74–86 85[27] M. Kondo, T. Oya-Ito, T. Kumagai, T. Osawa, K. Uchida, Cyclopentenone pros-
taglandins as potential inducers of intracellular oxidative stress, Journal of
Biological Chemistry 276 (15) (2001) 12076–12083. http://dx.doi.org/10.1074/
jbc.M009630200 11278531.
[28] U.K. Laemmli, Cleavage of structural proteins during the assembly of the head
of bacteriophage T4, Nature 227 (5259) (1970) 680–685 5432063.
[29] C. Ohlsson, N. Kley, H. Werner, D. LeRoith, p53 regulates insulin-like growth
factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphoryla-
tion in an osteosarcoma cell line: interaction between p53 and Sp1, En-
docrinology 139 (3) (1998) 1101–1107. http://dx.doi.org/10.1210/
endo.139.3.5832 9492043.
[30] S.B. Appleby, A. Ristimäki, K. Neilson, K. Narko, T. Hla, Structure of the human
cyclo-oxygenase-2 gene, Biochemical Journal 302 (3) (1994) 723–727
7945196.
[31] B. Li, M.Y. Lee, Transcriptional regulation of the human DNA polymerase delta
catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1, Journal of
Biological Chemistry 276 (32) (2001) 29729–29739. http://dx.doi.org/10.1074/
jbc.M101167200 11375983.
[32] G. Koutsodontis, I. Tentes, P. Papakosta, A. Moustakas, D. Kardassis, Sp1 plays a
critical role in the transcriptional activation of the human cyclin-dependent
kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein,
Journal of Biological Chemistry 276 (31) (2001) 29116–29125. http://dx.doi.
org/10.1074/jbc.M104130200 11384995.
[33] E.C. Thornborrow, J.J. Manfredi, The tumor suppressor protein p53 requires a
cofactor to activate transcriptionally the human BAX promoter, Journal of
Biological Chemistry 276 (19) (2001) 15598–15608. http://dx.doi.org/10.1074/
jbc.M011643200 11278953.
[34] A.R. Black, D. Jensen, S.Y. Lin, J.C. Azizkhan, Growth/cell cycle regulation of Sp1
phosphorylation, Journal of Biological Chemistry 274 (3) (1999) 1207–1215
9880488.
[35] J.F. Schmedtje Jr., Y.-S. Ji, W.-L. Liu, R.N. DuBois, M.S. Runge, Hypoxia induces
cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vas-
cular endothelial cells, Journal of Biological Chemistry 272 (1) (1997) 601–608
8995303.
[36] A. Ciechanover, The ubiquitin–proteasome proteolytic pathway, Cell 79 (1)
(1994) 13–21 7923371.
[37] M. Hochstrasser, Ubiquitin, proteasomes, and the regulation of intracellular pro-
tein degradation, Current Opinion in Cell Biology 7 (2) (1995) 215–223 7612274.
[38] S. Jentsch, S. Schlenker, Selective protein degradation: a journey's end within
the proteasome, Cell 82 (6) (1995) 881–884 7553848.
[39] K. Uchida, 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress,
Progress in Lipid Research 42 (4) (2003) 318–343 12689622.
[40] U. Schönbeck, G.K. Sukhova, P. Graber, S. Coulter, P. Libby, Augmented ex-
pression of cyclooxygenase-2 in human atherosclerotic lesions, American
Journal of Pathology 155 (4) (1999) 1281–1291. http://dx.doi.org/10.1016/
S0002-9440(10)65230-3 10514410.
[41] L. Ho, C. Pieroni, D. Winger, D.P. Purohit, P.S. Aisen, G.M. Pasinetti, Regional
distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's
disease, Journal of Neuroscience Research 57 (3) (1999) 295–303 10412020.
[42] E.A. Meagher, O.P. Barry, A. Burke, M.R. Lucey, J.A. Lawson, J. Rokach, G.
A. FitzGerald, Alcohol-induced generation of lipid peroxidation products in
humans, Journal of Clinical Investigation 104 (6) (1999) 805–813. http://dx.
doi.org/10.1172/JCI5584 10491416.
[43] C.J. Li, A.A. Nanji, A.N. Siakotos, R.C. Lin, Acetaldehyde-modiﬁed and 4-hy-
droxynonenal-modiﬁed proteins in the livers of rats with alcoholic liver dis-
ease, Hepatology 26 (3) (1997) 650–657. http://dx.doi.org/10.1002/
hep.510260317 9303495.
[44] R.N. DuBois, J. Awad, J. Morrow, L.J. Roberts 2nd, P.R. Bishop, Regulation of
eicosanoid production and mitogenesis in rat intestinal epithelial cells by
transforming growth factor-alpha and phorbol ester, Journal of Clinical In-
vestigation 93 (2) (1994) 493–498. http://dx.doi.org/10.1172/JCI116998
8113389.
[45] T.P. Misko, J.L. Trotter, A.H. Cross, Mediation of inﬂammation by en-
cephalitogenic cells: interferon gamma induction of nitric oxide synthase and
cyclooxygenase 2, Journal of Neuroimmunology 61 (2) (1995) 195–204. http:
//dx.doi.org/10.1016/0165-5728(95)00091-F 7593555.
[46] Q.R. Chen, C. Miyaura, S. Higashi, M. Murakami, I. Kudo, S. Saito, T. Hiraide,
Y. Shibasaki, T. Suda, Activation of cytosolic phospholipase A2 by platelet-
derived growth factor is essential for cyclooxygenase-2-dependent pros-
taglandin E2 synthesis in mouse osteoblasts cultured with interleukin-1,
Journal of Biological Chemistry 272 (9) (1997) 5952–5958. http://dx.doi.org/
10.1074/jbc.272.9.5952 9038215.
[47] D.J. Perkins, D.A. Kniss, Rapid and transient induction of cyclo-oxygenase 2 by
epidermal growth factor in human amnion-derived WISH cells, Biochemical
Journal 321 (3) (1997) 677–681 9032453.
[48] S.R. Adderley, D.J. Fitzgerald, Oxidative damage of cardiomyocytes is limited
by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-
2, Journal of Biological Chemistry 274 (8) (1999) 5038–5046. http://dx.doi.org/
10.1074/jbc.274.8.5038 9988750.
[49] K. Shinmura, X.L. Tang, Y. Wang, Y.T. Xuan, S.Q. Liu, H. Takano, A. Bhatnagar,
R. Bolli, Cyclooxygenase-2 mediates the cardioprotective effects of the late
phase of ischemic preconditioning in conscious rabbits, Proceedings of the
National Academy of Sciences of the United States of America 97 (18) (2000)
10197–10202. http://dx.doi.org/10.1073/pnas.97.18.10197 10963682.
[50] K.K. Steinauer, I. Gibbs, S. Ning, J.N. French, J. Armstrong, S.J. Knox, Radiation
induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells,International Journal of Radiation Oncology—Biology–Physics 48 (2) (2000)
325–328. http://dx.doi.org/10.1016/S0360-3016(00)00671-4 10974444.
[51] S.L. Kargman, G.P. O’Neill, P.J. Vickers, J.F. Evans, J.A. Mancini, S. Jothy, Ex-
pression of prostaglandin G/H synthase-1 and -2 protein in human colon
cancer, Cancer Research 55 (12) (1995) 2556–2559 7780968.
[52] H. Sano, Y. Kawahito, R.L. Wilder, A. Hashiramoto, S. Mukai, K. Asai, S. Kimura,
H. Kato, M. Kondo, T. Hla, Expression of cyclooxygenase-1 and -2 in human
colorectal cancer, Cancer Research 55 (17) (1995) 3785–3789 7641194.
[53] A. Ristimäki, N. Honkanen, H. Jänkälä, P. Sipponen, M. Härkönen, Expression of
cyclooxygenase-2 in human gastric carcinoma, Cancer Research 57 (7) (1997)
1276–1280 9102213.
[54] K. Müller-Decker, K. Scholz, F. Marks, G. Fürstenberger, Differential expression
of prostaglandin H synthase isozymes during multistage carcinogenesis in
mouse epidermis, Molecular Carcinogenesis 12 (1) (1995) 31–41. http://dx.doi.
org/10.1002/mc.2940120106 7818763.
[55] M. Parrett, R. Harris, F. Joarder, M. Ross, K. Clausen, F. Robertson, Cyclooxygenase-2
gene expression in human breast cancer, International Journal of Oncology 10 (3)
(1997) 503–507. http://dx.doi.org/10.3892/ijo.10.3.503 21533404.
[56] U. Santhanam, A. Ray, P.B. Sehgal, Repression of the interleukin 6 gene pro-
moter by p53 and the retinoblastoma susceptibility gene product, Proceedings
of the National Academy of Sciences of the United States of America 88 (17)
(1991) 7605–7609. http://dx.doi.org/10.1073/pnas.88.17.7605 1652755.
[57] E. Seto, A. Usheva, G.P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A.
J. Levine, T. Shenk, Wild-type p53 binds to the TATA-binding protein and re-
presses transcription, Proceedings of the National Academy of Sciences of the
United States of America 89 (24) (1992) 12028–12032. http://dx.doi.org/
10.1073/pnas.89.24.12028 1465435.
[58] D.H. Mack, J. Vartikar, J.M. Pipas, L.A. Laimins, Speciﬁc repression of TATA-
mediated but not initiator-mediated transcription by wild-type p53, Nature
363 (6426) (1993) 281–283. http://dx.doi.org/10.1038/363281a0 8387645.
[59] X. Kong, B. Peng, Y. Yang, P. Zhang, B. Qin, D. Han, C. Wang, Y. Dang, J.O. Liu,
L. Yu, p53 represses transcription of RING ﬁnger LIM domain-binding protein
RLIM through Sp1, PLOS One 8 (5) (2013) e62832. http://dx.doi.org/10.1371/
journal.pone.0062832 23650532.
[60] Q. Xu, Y.S. Ji, J.F. Schmedtje Jr., Sp1 increases expression of cyclooxygenase-2 in
hypoxic vascular endothelium. Implications for the mechanisms of aortic
aneurysm and heart failure, Journal of Biological Chemistry 275 (32) (2000)
24583–24589. http://dx.doi.org/10.1074/jbc.M003894200 10825178.
[61] S.K. Dhar, Y. Xu, Y. Chen, D.K. St Clair, Speciﬁcity protein 1-dependent p53-
mediated suppression of human manganese superoxide dismutase gene ex-
pression, Journal of Biological Chemistry 281 (31) (2006) 21698–21709. http:
//dx.doi.org/10.1074/jbc.M601083200 16740634.
[62] B.H. Cai, P.C. Hsu, I.L. Hsin, C.F. Chao, M.H. Lu, H.C. Lin, S.H. Chiou, P.L. Tao, J.
Y. Chen, p53 acts as a co-repressor to regulate keratin 14 expression during
epidermal cell differentiation, PLOS One 7 (7) (2012) e41742. http://dx.doi.org/
10.1371/journal.pone.0041742 22911849.
[63] T.M. Gottlieb, J.F. Leal, R. Seger, Y. Taya, M. Oren, Cross-talk between Akt, p53
and Mdm2: possible implications for the regulation of apoptosis, Oncogene 21
(8) (2002) 1299–1303. http://dx.doi.org/10.1038/sj.onc.1205181 11850850.
[64] L.D. Mayo, D.B. Donner, A phosphatidylinositol 3-kinase/Akt pathway pro-
motes translocation of Mdm2 from the cytoplasm to the nucleus, Proceedings
of the National Academy of Sciences of the United States of America 98 (20)
(2001) 11598–11603. http://dx.doi.org/10.1073/pnas.181181198 11504915.
[65] Y. Ogawara, S. Kishishita, T. Obata, Y. Isazawa, T. Suzuki, K. Tanaka,
N. Masuyama, Y. Gotoh, Akt enhances Mdm2-mediated ubiquitination and
degradation of p53, Journal of Biological Chemistry 277 (24) (2002)
21843–21850. http://dx.doi.org/10.1074/jbc.M109745200 11923280.
[66] S.J. Lee, K.W. Seo, M.R. Yun, S.S. Bae, W.S. Lee, K.W. Hong, C.D. Kim, 4-hydro-
xynonenal enhances MMP-2 production in vascular smooth muscle cells via
mitochondrial ROS-mediated activation of the Akt/NF-kappaB signaling
pathways, Free Radical Biology and Medicine 45 (10) (2008) 1487–1492. http:
//dx.doi.org/10.1016/j.freeradbiomed.2008.08.022 18805481.
[67] S.M. Prescott, F.A. Fitzpatrick, Cyclooxygenase-2 and carcinogenesis, Biochi-
mica et Biophysica Acta 1470 (2) (2000) M69–M78. http://dx.doi.org/10.1016/
S0304-419X(00)00006-8 10722929.
[68] M. Tsujii, R.N. Dubois, Alterations in cellular adhesion and apoptosis in epi-
thelial cells overexpressing prostaglandin endoperoxide synthase 2, Cell 83 (3)
(1995) 493–501. http://dx.doi.org/10.1016/0092-8674(95)90127-2 8521479.
[69] M. Tsujii, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, R.N. Dubois, Cyclooxygenase
regulates angiogenesis induced by colon cancer cells, Cell 93 (5) (1998)
705–716. http://dx.doi.org/10.1016/S0092-8674(02)09420-5 9630216.
[70] O.C. Trifan, R.M. Smith, B.D. Thompson, T. Hla, Overexpression of cycloox-
ygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent
mechanism, Journal of Biological Chemistry 274 (48) (1999) 34141–34147.
http://dx.doi.org/10.1074/jbc.274.48.34141 10567385.
[71] A. Ristimäki, S. Garﬁnkel, J. Wessendorf, T. Maciag, T. Hla, Induction of cy-
clooxygenase-2 by interleukin-1alpha. Evidence for post-transcriptional reg-
ulation, Journal of Biological Chemistry 269 (16) (1994) 11769–11775 8163473.
[72] K. Tanaka, Proteasomes: structure and biology, Journal of Biochemistry 123 (2)
(1998) 195–204. http://dx.doi.org/10.1093/oxfordjournals.jbchem.a021922.
[73] K. Tanaka, T. Chiba, The proteasome: a protein-destroying machine, Genes
Cells 3 (8) (1998) 499–510. http://dx.doi.org/10.1046/j.1365-2443.1998.00207.
x 9797452.
[74] N. Tanahashi, H. Kawahara, Y. Murakami, K. Tanaka, The proteasome-depen-
dent proteolytic system, Molecular Biology Reports 26 (1–2) (1999) 3–9. http:
//dx.doi.org/
T. Kumagai et al. / Redox Biology 4 (2015) 74–868610.1023/A:1006909522731 10363639.
[75] Q. Ding, J.N. Keller, Proteasomes and proteasome inhibition in the central
nervous system, Free Radical Biology and Medicine 31 (5) (2001) 574–584
11522442.
[76] B. Halliwell, Hypothesis: proteasomal dysfunction: a primary event in neu-
rogeneration that leads to nitrative and oxidative stress and subsequent cell
death, Annals of the New York Academy 962 (2002) 182–194. http://dx.doi.
org/10.1111/j.1749-6632.2002.tb04067.x 12076974.
[77] P. Jenner, Oxidative stress in Parkinson's disease, Annals of Neurology 53
(2003) S26–S38. http://dx.doi.org/10.1002/ana.10483.
[78] D. Praticò, N. Delanty, Oxidative injury in diseases of the central nervous
system: focus on Alzheimer's disease, American Journal of Medicine 109 (7)
(2000) 577–585. http://dx.doi.org/10.1016/S0002-9343(00)00547-7
11063960.
[79] T. Shibata, T. Yamada, M. Kondo, N. Tanahashi, K. Tanaka, H. Nakamura,
H. Masutani, J. Yodoi, K. Uchida, An endogenous electrophile that modulatesthe regulatory mechanism of protein turnover: inhibitory effects of
15-deoxy-Δ12,14-prostaglandin J2 on proteasome, Biochemistry 42 (47) (2003)
13960–13968. http://dx.doi.org/10.1021/bi035215a 14636064.
[80] M. Aki, T. Tamura, F. Tokunaga, S. Iwanaga, Y. Kawamura, N. Shimbara,
S. Kagawa, K. Tanaka, A. Ichihara, cDNA cloning of rat proteasome subunit RC1,
a homologue of RING10 located in the human MHC class II region, FEBS Letters
301 (1) (1992) 65–68. http://dx.doi.org/10.1016/0014-5793(92)80211-X
1451788.
[81] B.A. Ballif, N.V. Mincek, J.T. Barratt, M.L. Wilson, D.L. Simmons, Interaction of
cyclooxygenases with an apoptosis- and autoimmunity-associated protein,
Proceedings of the National Academy of Sciences of the United States of
America 93 (11) (1996) 5544–5549. http://dx.doi.org/10.1073/pnas.93.11.5544
8643612.
